It should be hoped that TKIs, mTORIs with novel therapies (anti-PDL1, anti-PD1 anti-CTLA4) used in combination or sequentially have potential to provide best treatment and favorable outcomes in ccRCC. This evidence concerns the gene CD274 and nonpapillary renal cell carcinoma.